« New nurse guidelines launched for COPD | Entrada | European Oncology Nursing Society (EONS) Calls For Adopting New Guidelines Across Europe To Protect Nurses And Patients Involved In Cancer Treatment »

June 06, 2008

Safety With Injectable Medicines Implementing The NPSA Alert, UK

Baxter Healthcare launched today an Educational Programme to support hospitals in the implementation of the recently released NPSA Safety Alert 20 - Promoting safer use of injectable medicines. The Baxter sponsored programme has been developed and organised by an NHS Working Group consisting of senior Pharmacists, Nurses and Clinicians.

The programme is aimed at Chief/Head 'Pharmacists, Clinical Nurse Specialists, Consultant Anaesthetists, Clinical Governance and Risk Managers and anyone who will be involved in implementation of the alert.

Two one day training events are scheduled; London on the 13th June and Harrogate on 25th June. There is a full agenda planned for the day, focusing very much on the practical implementation of the alert, and will include presentations, scenario planning workshops and an opportunity to share learnings and ideas. Attendees will receive a resource pack including all of the speaker's presentations and a How to Guide to facilitate reproduction of a similar event in their own health authority to other members of staff.

"As intravenous therapy becomes steadily more complex and use of potent, "high-tech" drugs more commonplace, the chance of mistakes in prescribing, preparation or administration also increases, with a consequent risk of harm to patients. The NPSA Safety Alert 20 highlights the key risk issues and makes detailed recommendations to the NHS about how to minimise them. This study day is designed to introduce the Alert to senior NHS clinical staff and to support local implementation of its recommendations." Tim Root, Specialist Pharmacist, Clinical Governance and Technical Services, London, Eastern & South East Specialist Pharmacy Services.

There is no charge for attendance but there are a limited number of spaces for each day, early registration is recommended. To find out more and register to attend contact patient_safety_uk@baxter.com

-- Baxter Healthcare's sponsorship of the event includes financial and logistical support to enable the Education Programme.

-- Baxter Healthcare Ltd. is the primary domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists health-care professionals and their patients with treatment of complex medical conditions, including cancer, haemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

-- The content of the Educational Programme has been developed and organised by an NHS Working Group comprised of:

- Prof. Ray Fitzpatrick: Clinical Director Pharmacy, Royal Wolverhampton Hospitals NHS Trust
- Jill Kayley, Independent Nurse Consultant
- Prof. David Cousins: Head of Safe Medication Practices, NPSA
- Richard Hey, Director of Pharmacy, Manchester Royal Infirmary
- Victor Standing, Liverpool Royal infirmary
- Anne Black, QA Pharmacist, Freeman Hospital
- Dr. Dominic Bell, Consultant in Intensive Care/Anaesthesia, Leeds General Infirmary
- Gillian Cavell: Associate Director for Pharmacy, King's College Hospital NHS Trust
- Ian M. Beaumont, Director Quality Control North West-.Regional Quality
- Tim Root, Specialist Pharmacist, Clinical Governance and Technical Services, London, Eastern & South East Specialist Pharmacy Services

-- The NPSA safety alert 20, "Promoting Safer Use of Injectable Medicines" was released on 28 March 2007. The alert covers multi-professional safer practice standards with particular emphasis on prescribing, preparation and administration of injectable medicines in clinical areas. The alert must be fully implemented by 31 March 2008

-- NPSA Patient safety alert 20: Promoting safer use of injectable medicines

Research evidence indicates that the incidence of errors in prescribing, preparing and administering injectable medicines is higher than for other forms of medicine. In one study, at least one error occurred in 49 per cent of intravenous medicine doses prepared and administered on hospital wards; one per cent of errors were judged to be potentially severe; and 29 per cent potentially moderate errors.

Using data from the NRLS and other evidence, the NPSA has identified a number of latent system risks and is making recommendations that can make the use of injectable medicines safer. These recommendations are published in the form of an alert and are supported by a range of supporting materials to aid implementation and embed safer practice: 1

1. npsa.nhs.uk/display?contentId=5755 Web page accessed 28 March 07

Baxter Healthcare Ltd.
Wallingford Road, Compton
Newbury, Berkshire RG20 7QW

Publicado por Andrea Cane às June 6, 2008 10:47 PM